SEC Comment Letter for Inmune Bio, Inc. (INMB) (CIK 0001711754) (INMB) — Mar 31, 2020
Inmune Bio, Inc. (INMB) (CIK 0001711754)
Date: March 31, 2020 · CIK: 0001711754 · Accession: 0000000000-20-002785
AI Filing Summary & Sentiment
File numbers found in text: 333-237368
Letter
March 31, 2020 Raymond J. Tesi, M.D. Chief Executive Officer Inmune Bio, Inc. 1200 Prospect Street, Suite 525 La Jolla, CA 92037 Re:Inmune Bio, Inc. Registration Statement on Form S-3 Filed March 24, 2020 File No. 333-237368 Dear Dr. Tesi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David B. Manno, Esq.
Show Raw Text
March 31, 2020
Raymond J. Tesi, M.D.
Chief Executive Officer
Inmune Bio, Inc.
1200 Prospect Street, Suite 525
La Jolla, CA 92037
Re:Inmune Bio, Inc.
Registration Statement on Form S-3
Filed March 24, 2020
File No. 333-237368
Dear Dr. Tesi:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David B. Manno, Esq.